ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,63
0,11%
Bitcoin
59 141,49
1,55%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Agile Therapeutics Inc (AGRX)

  7. Agile Therapeutics Inc (AGRX) Actualités

AGRX Agile Therapeutics Inc

0,6022
0,00 (0,00%)
Après les heures de négociation
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Agile Therapeutics Inc AGRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,6022 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,6022 0,6022
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
28/3/202413:05GLOBEAgile Therapeutics Reports Fourth Quarter & Full Year 2023..
25/3/202421:30GLOBEAgile Therapeutics Announces Delisting from Nasdaq
21/3/202411:35GLOBECorrection - Agile Therapeutics to Report Fourth Quarter and..
20/3/202413:15GLOBEAgile Therapeutics to Report Fourth Quarter and Full Year..
13/3/202412:31GLOBEAgile Therapeutics Completes Pay-off of Debt and Remains..
23/2/202422:57EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/2/202422:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/2/202415:01GLOBEAgile Therapeutics Announces Exercise of Warrants for $4.8..
15/2/202422:45EDGAR2Form 8-K - Current report
15/2/202422:30GLOBEAgile Therapeutics Announces Extension Granted by Nasdaq..
14/2/202402:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:51EDGAR2Form S-1/A - General form for registration of securities..
06/2/202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202415:21EDGAR2Form S-1/A - General form for registration of securities..
02/2/202422:27EDGAR2Form S-1/A - General form for registration of securities..
23/1/202415:29GLOBEThe Biden-Harris Administration Announces New Guidance to..
20/12/202314:00EDGAR2Form S-1/A - General form for registration of securities..
12/12/202314:01GLOBEAgile Therapeutics Provides Update on Actions Being Taken to..
11/12/202323:30EDGAR2Form S-1 - General form for registration of securities under..
06/12/202314:00EDGAR2Form 8-K - Current report
04/12/202314:00EDGAR2Form 8-K - Current report
09/11/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:15EDGAR2Form 8-K - Current report
09/11/202314:05GLOBEAgile Therapeutics Reports Third Quarter 2023 Financial..
26/10/202314:05GLOBEAgile Therapeutics to Report Third Quarter 2023 Financial..
04/10/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202322:30GLOBEAgile Therapeutics Reports an Inducement Grant to New Chief..
02/10/202322:30EDGAR2Form 8-K - Current report
28/9/202322:50EDGAR2Form 8-K - Current report
05/9/202314:05GLOBEAgile Therapeutics to Present at the H.C. Wainwright 25th..
25/8/202322:02EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202314:30EDGAR2Form 8-K/A - Current report: [Amend]
09/8/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202314:10EDGAR2Form 8-K - Current report
09/8/202314:05GLOBEAgile Therapeutics Reports Second Quarter 2023 Financial..
26/7/202314:30GLOBEAgile Therapeutics to Report Second Quarter 2023 Financial..
30/6/202322:50EDGAR2Form 8-K - Current report
30/6/202322:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202322:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202322:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202322:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202314:01GLOBEAgile Therapeutics Announces the Availability of Twirla® to..
23/6/202318:05GLOBEAgile Therapeutics Commends the Biden Administration’s..
15/6/202322:05GLOBEAgile Therapeutics Announces the Availability of Twirla®..
13/6/202322:05GLOBEAgile Therapeutics Announces New Agreement with vitaCare®..
25/5/202322:05GLOBEAgile Therapeutics Announces Closing of $7.5 Million Public..
23/5/202302:00GLOBEAgile Therapeutics Announces Pricing of $7.5 Million Public..
11/5/202322:05GLOBEAgile Therapeutics Reports First Quarter 2023 Financial..
08/5/202314:00GLOBEAgile Therapeutics to Report First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
AGRX
Agile Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés